POSTINFECTIOUS IRRITABLE BOWEL SYNDROME


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

Article presents an overview of the current state of the data problems postinfectiousirritable bowel syndrome (PI-IBS) and own results of observation of 30 patients with PI-IBS. The study demonstrated the efficacy of a combined preparation of butyric acid and inulinin the complex therapy of PI-IBS.

全文:

受限制的访问

作者简介

Yu. USPENSKAYA

I.M. Sechenov First Moscow Medical University

Email: jusp@mail.ru
Candidate of Medical Sciences

参考

  1. Захаренко С.М. Невсасывающиеся антибиотики в терапии острых кишечных инфекций // Рус. мед. журн. (Болезни органов пищеварения). -2009; 11 (1): 28-32.
  2. Ручкина И.Н., Фадеева Н.А., Парфенов А.И. и др. Роль микрофлоры тонкой кишки в развитии вторичной лактазной недостаточности и возможности ее лечения пробиотиками // Тер. архив. - 2013; 85 (2): 21-6.
  3. Alajbegovic S., Sanders J., Atherly D. et al. Effectiveness of rifaximin and fluoroquinolones in preventing travelers’ diarrhea (TD): a systematic review and meta-analysis // Syst. Rev. - 2012; 1: 39.
  4. Atkinson W., Lockhart S., Whorwell P. et al. Altered 5-hydroxytryptamine signaling in patients with constipation- and diarrhea-predominant irritable bowel syndrome // Gastroenterology. - 2006; 130 (1): 34-43.
  5. Barrett J., Gibson P. Fermentable oligosaccharides, disaccharides, monosaccharides and polyols (FODMAPs) and nonallergic food intolerance: FODMAPs or food chemicals? // Ther. Adv. Gastroenterol. - 2012; 5: 261-8.
  6. Bocker U. et al. Responsiveness of intestinal epithelial cell lines to lipopolysaccharide is correlated with Toll-like receptor 4 but not Toll-like receptor 2 or CD14 expression // Int. J. Colorectal. Dis. - 2003; 18: 25-32
  7. Brenner D., Moeller M., Chey W. et al. The utility of probiotics in the treatment of irritable bowel syndrome: a systematic review // Am. J. Gastroenterol. - 2009; 104: 1033-49
  8. Canani R. et al. Butyrate as an effective treatment of congenital chloride diarrhea // Gastroenterology. - 2004; 127: 630-4.
  9. Cavaglieri C. et al. Differential effects of short-chain fatty acids on proliferation and production of pro- and anri-irnflammatorycytochines by cultured lymphocytes // Life Sci. - 2003; 15: 1683-90.
  10. Chaudhary N., Truelove S. The irritable colon syndrome. A study of the clinical features, predisposing causes, and prognosis in 130 cases // Q. J. Med. -1962; 31: 307-22.
  11. Douglas K. Rex. Add Parasites to the Causes of Postinfectious Irritable Bowel Syndrome // Gut. - 2012; 61 (2): 214.
  12. Dunlop S., Coleman N., Blackshaw E. et al. Abnormalities of 5-hydroxytryptamine metabolism in irritable bowel syndrome // Clin. Gastroenterol. Hepatol. - 2005; 3 (4): 349-57.
  13. Dunlop S., Jenkins D., Neal K. et al. Relative importance of enterochromaffin cell hyperplasia, anxiety, and depression in postinfectious IBS // Gastroenterology. -2003; 125 (6): 1651-9.
  14. Elsenbruch S. Abdominal pain in irritable bowel syndrome: a review of putative psychological, neural and neuro-immune mechanisms // Brain Behav. Immun. - 2011; 25: 86-94.
  15. Fernandez-Banares F., Esteve M., Viver J. Fructose-sorbitol malabsorption // Curr. Gastroenterol. Rep. - 2009; 11 (5): 368-74.
  16. Gonsalkorale W., Perrey C., Pravica V. et al. Interleukin 10 genotypes in irritable bowel syndrome: evidence for an inflammatory component? // Gut. - 2003; 52 (1): 91-3.
  17. Gwee K., Graham J., McKendrick M. et al. Psychometric scores and persistence of irritable bowel after infectious diarrhea // Lancet. - 1996; 347 (8995): 150-3.
  18. Gwee K., Leong Y., Graham C. et al. The role of psychological and biological factors in postinfective gut dysfunction // Gut. - 1999; 44 (3): 400-6.
  19. Halpern G., Prindiville T., Blankenburg M. et al. Treatment of irritable bowel syndrome with Lacteol Fort: a randomized, double-blind, cross-over trial // Am. J. Gastroenterol. - 1996; 91: 1579-85.
  20. Jalanka-Tuovinen J., Salojärvi J., Salonen A. et al. Faecalmicrobiota composition and host-microbe cross-talk following gastroenteritis and in postinfectious irritable bowel syndrome // Gut. - 2013; doi: 10.1136/ gutjnl-2013-305994.
  21. Kanuachi O. et al. Butyrate from bacterial fermentation of germinated barley foodstuff preserves intestinal barrier function in experimental colitis in the rat model // Gastroenterol. Hepatol. - 1999; 14: 880-8.
  22. Keating C., Beyak M., Foley S. et al. Afferent hypersensitivity in a mouse model of post-inflammatory gut dysfunction: role of altered serotonin metabolism // J. Physiol. - 2008; 586: 4517-30.
  23. Langhorst J., Junge A., Rueffer A. et al. Elevated human ß-defensin-2 levels indicate an activation of the innate immune system in patients with irritable bowel syndrome // Am. J. Gastroenterol. - 2009; 104: 404-10.
  24. Lee K., Kim Y., Kim J. et al. The alteration of enterochromaffin cell, mast cell, and lamina propria T lymphocyte numbers in irritable bowel syndrome and its relationship with psychological factors // J. Gastroenterol. Hepatol. - 2008; 23: 1689-94.
  25. Marshall J., Thabane M., Garg A. et al. Incidence and epidemiology of irritable bowel syndrome after a large waterborne outbreak of bacterial dysentery // Gastroenterology. - 2006; 131: 445-50.
  26. McKernan D., Gaszner G., Quigley E. et al. Altered peripheral toll-like receptor responses in the irritable bowel syndrome // Aliment. Pharmacol. Ther. -2011; 33 (9): 1045-52.
  27. McKernan D., Fitzgerald P., Dinan T. et al. The probiotic Bifidobacterium infantis 35624 displays visceral antinociceptive effects in the rat // Neurogastroenterol. Motil. - 2010; 22: 1029-35.
  28. Neal K., Hebden J., Spiller R. Prevalence of gastrointestinal symptoms six months after bacterial gastroenteritis and risk factors for development of the irritable bowel syndrome: postal survey of patients // BMJ. - 1997; 314: 779-82.
  29. O’Mahony L., McCarthy J., Kelly P. et al. Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles // Gastroenterology. - 2005; 128: 541-51.
  30. Pimentel M., Lembo A., Chey W. et al. Rifaximin therapy for patients with irritable bowel syndrome without constipation // N. Engl. J. Med. - 2011; 364: 22-32.
  31. Rodriguez L., Ruigomez A. Increased risk of irritable bowel syndrome after bacterial gastroenteritis: cohort study // BMJ. - 1999; 318 (7183): 565-6.
  32. Rodriguez-Cabezas M. et al. Dietary fiber down-regulates colonic tumor necrosis factor alpha and nitric oxide production in trinitrobenzenesulfonic acid-induced colitic rats // J. Nutr. - 2002; 132: 3267-71.
  33. Spence M., Moss-Morris R. The cognitive behavioural model of irritable bowel syndrome: a prospective investigation of patients with gastroenteritis // Gut. - 2007; 56 (8): 1066-71.
  34. Spiller R., Jenkins D., Thornley J. et al. Increased rectal mucosal enteroendocrine cells, T-lymphocytes and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome // Gut. - 2000; 47: 804-11.
  35. Sykes M., Blanchard E., Lackner J. et al. Psychopathology in irritable bowel syndrome: support for a psychophysiological model // J. Behav. Med. - 2003; 26: 361-72.
  36. Thabane M., Simunovic M., Akhtar-Danesh N. et al. An outbreak of acute bacterial gastroenteritis is associated with an increased incidence of irritable bowel syndrome in children // Am. J. Gastroenterol. - 2010; 105: 933-9.
  37. Triantafillidis J., Peros G. Post-infectious Irritable bowel syndrome // Ann. Gastroenterol. - 2007; 20 (4): 243-5.
  38. Vidyasagar S. et al. Effects of butyrate on active sodium and chloride transport in rat and rabbit distal colon // J Physiol. - 2002; 539: 163-73.
  39. Wehkamp J., Fellerman K., Herrlinger K. et al. Human ß-defensin 2 but not ß-defensin 1 is expressed preferentially in colonic mucosa of inflammatory bowel disease // Eur. J. Gastroenterol. Hepatol. - 2002; 14: 745-52.

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Russkiy Vrach Publishing House, 2014
##common.cookie##